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Abstract 
Introduction: The purpose of this meta-analysis was to determine the 
efficacy of proton pwnp inhibitors (PPI) in preventing recurrent bleeding 
and death in bleeding peptic ulcer. 
Methods: PubMed and hand searching of cited references was used to 
identify relevant studies comparing PPI to either placebo or histamine 2 
receptor antagonists for the prevention of rebleeding or death. Non english 
studies were translated Quality assessment and data extraction was 
perfomed by 2 independent reviewers. The RevMan statistical software was 
used to combine studies with the peto method. 
Results: 15 studies with a total of3063 patients enrolled were included. 
The pooled Odds Ratio(pOR) for the use ofPPI to prevent rebleeding was 
significant at 0.55 (95%CI 0.46-0.66). There was a reduction in rebleeding 
regardless of whether or not therapeutic endoscopy had been used. Infusions 
ofPPI were most beneficial with a pOR of0.40 (0.29-53) with a number 
needed to treat to prevent 1 rebleed of only5 while bolus injections failed to 
provide any benefit over control medication. There was no difference in 
mortality between PPI and control groups. 
Discussion: PPI are effective for the prevention of rebleeding in peptic 
ulcer disease regardless of whether or not therapeutic endoscopy has been 
employed. PPI are most effective when given as an infusion. Intravenous 
PPI should only be used in high risk peptic ulcer bleeding. Further 
investigations are required to determine the role of oral PPI for the 
prevention of rebleeding as only 2 studies used oral PPI. 
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1.0 Introduction 
1.1 Definition of meta-analysis 
Meta-analysis is a tool which has become very popular in medical literature. It 
involves the process of critically reviewing all the available literature on a selected 
topic. Most meta-analyses involve assessing treatment effect, that is whether or 
not a certain treatment will or will not improve disease outcome. The quality of 
the study is assessed and relevant qualitative data are extracted. Quantitative data 
are then extracted and combined mathematically yielding an overall estimate of 
the treatment effect. Thus, meta-analysis involves both qualitative and 
quantitative synthesis. 
The definition of meta-analysis has varied since it was first introduced. In 
1959, Mantel and Haenzel wrote their landmark paper describing the statistical 
aspects of combining data from retrospective studies1• However, it was not until 
1976 that the term meta-analysis was actually used for the first time2• Since then, 
it has become a very valuable tool to quantify the overall effect of many therapies 
and to help clinicians in the decision making process. 
Meta-analyses are also referred to as systemic reviews as well as overviews. 
However, there are significant differences between a meta-analysis and a 
traditional narrative review. Narrative reviews often reflect the opinion and 
potential bias of the authors. One such criticism of the narrative review compared 
it to an essay being written by a student; "if you found something that did not fit 
your theory, you left it out. "3 The systematic review of the literature decreases 
bias and meta-analysis by mathematically pools the data strengtheng the 
conclusions reached compared to that of traditional reviews. 
Meta-analysis is now an accepted research tool. Journals such as Evidenced 
Based Medicine and ACP Journal Club review current medical literature and often 
include meta-analyses in their reviews4• Consensus groups often refer to meta-
analyses to summarize the best available data5• Currently, conclusions reached in 
meta-analysis is considered level 1 evidence used to support or contradict medical 
therapeutics, which is on par with RCTs and cohort studies. 
Completing a meta-analysis is analogous to performing a randomized controlled 
trial. There is a defined stepwise approach which begins with the formulation of a 
question or hypothesis. One then needs to determine which features are or are not 
needed in the experimental or control groups. Next, rather than performing an 
experiment or clinical trial to gather data, data are gathered by reviewing 
completed research projects. Analysis of the data involves applying the Mantel-
Haenzel test or a variation of it to pool the data and to draw conclusions. 
1.2 Formulating a Question 
Most meta-analyses performed arise from questions encountered in every day 
clinical work. The question must be clinically relevant and generally arises from 
our own lack of knowledge. In fact, many of the queries are raised by our patients. 
It is important to formulate a question which has been well thought out. "Ask a 
poor question and you will get a poor review."6 For example, there is a 
significant difference in the following questions: 
1. Does acid suppression reduce poor outcomes in upper gastrointestinal bleeding 
(UGIB)? 
2. Does the use of Proton Pump Inhibitors(PPI) in UGIB from peptic ulcer reduce 
the incidence of rebleeding or mortality? 
The first question raises the possibility of multiple interventions such as oral 
antacids ( eg. calcium and magnesium hydroxide), Histamine 2 Receptor 
Antagonists{H2RA), PPI and even somatostatin. Question 1 also raises the 
possibility of many different sources of UGIB which include many different 
etiologies. Finally, question 1 does not specify which outcomes are important. 
Clinical studies on bleeding may utilize several different outcomes such as 
rebleeding, need for blood transfusion, need for surgery or death. In contrast, 
question 2 is quite specific in identifying the intervention to be examined, the 
specific disease entity and the outcomes of interest. 
Even with a well formulated question, there exists the probability that different 
studies will define endpoints differently. This is not a problem when it comes to 
an endpoint such as mortality but could very well be important in endpoints such 
as rebleeding. Therefore, it is important to precisely define what.is considered to 
be relevant rebleeding prior to carrying on to the next step in performing meta-
analysis. If studies use similar definitions for the endpoints of interest, 
heterogeniety may be reduced into the meta-analysis and the end result is likely to 
be more reliable. 
1.3 Determining Study Criteria 
Before setting out to find all of the information one can on the topic of interest, 
the study characteristics of the trials to be included in the meta-analysis need to be 
determined. When comparing this process to the randomized controlled trial, it is 
analogous to deciding on inclusion and exclusion criteria for the sample 
population. However, in a meta-analysis, we are determining the inclusion and 
exclusion criteria for the studies which will be included from those retrieved in the 
search. 
The inclusion and exclusion criteria will depend on the question being asked. In 
the typical situation, the effect of a treatment is being examined and several 
variables need to be determined. These variables concern the study population, 
treatment allocation (ie: whether the study was a randomized control trial or an 
observational or retrospective study) and the outcome. Other factors inherently 
linked to the study design include issues such as randomization, blinding of 
treatment allocation and blinding of the outcome assessment. These issues will be 
discussed later in the section on quality assessment. 
There are many different methods to examine the efficacy of a treatment. These 
include retrospective studies, historically controlled studies and prospective 
randomized controlled trials (RCT). Retrospective studies and studies using 
historical controls have several potential sources of bias with the most important 
one being treatment allocation or allocation bias. The RCT, on the other hand, 
minimizes allocation bias by randomizing patients provided there is blinding of 
the allocation process. Therefore, the most important inclusion criteria for a study 
to be included in a meta-analysis is that it be randomized particularly when 
dealing with trials oftherapy. 
The study population should be well described. Comparing groups with similar 
characteristics may strengthen the meta-analysis (using a single disease process is 
less likely to introduce heterogeneity). In the example used previously, patients 
with PUD bleeding may respond differently to a potential therapy than those with 
either varices or a Mallory Weiss tear. Therefore, the characteristics of the study 
population from any article should match those set out before retrieval begins. 
That is, many articles are discovered in the retrieval process but they all need to be 
examined to determine whether or not they will be included or excluded from the 
meta-analysis. The study enrollment of various papers affects how generalizable 
the results are to other populations of interest (age, gender, race etc.) 
There are many potential differences in treatment. There are different 
medication formulations such as oral and injectable forms or formulations from 
different manufacturers. One needs to determine a-priori whether studies using 
different methods of treatment should be combined or analyzed separately. The 
timing of the administration of the treatment may also be important. In the case of 
peptic ulcer bleeding, one would prefer to see the medication given as soon as the 
diagnosis has been established. Other factors related to the treatment would 
include an adequate description of the dose used and how it was administered: 
orally, bolus intravenous infusion, continuous intravenous infusion, subcutaneous 
or intra-muscular injections. 
The remaining issue for determining inclusion and exclusion criteria is the 
outcome of interest. Outcomes need clear definitions and should ideally be 
assessed by an observer who is unaware of the treatment allocation. For mortality, 
there is only one definition but some studies may differentiate between disease 
related mortality or overall mortality. However, rebleeding may be defined in 
several ways. First, it could be the appearance of bloody aspirate from a nasa-
gastric tube, observed bleeding at repeat endoscopy or it may have a more clinical 
definition such as recurrent hematemesis or melena associated with hemodynamic 
changes or a significant fall in hemoglobin. Therefore, since it is always possible 
that an endpoint may have different definitions, the endpoint should be clearly 
defined prior to retrieving any study. 
Once the issues of patient population, treatment allocation and outcome 
assessment have been addressed, it is likely that the type of studies to be included 
in the analysis has already been determined. That is, if the purpose of the meta-
analysis is to examine the efficacy of a therapeutic intervention, then one would 
preferably include only prospective randomized studies. However, the decision to 
include other studies such as those with a historical control group may be 
tempered by the availability of data. Furthermore, not all randomized studies will 
be double blind, thus a similar decision will need to be made with how to deal 
with these studies. Ideally, the double blind RCT would provide the best source of 
data as it is the "gold standard" of evidence for clinical medicine. 
Data may also be found in full peer reviewed articles or in abstract form. The 
fully published paper offers significant advantages over the abstract in that 
methodology can be clearly outlined and critically appraised. There are often gaps 
in both the methods and results from abstracts. There is no clear consensus on 
how to deal with data from abstracts. The data from abstracts may be included in 
the primary analysis or included later in a sensitivity analysis. By including the 
data from abstracts, one can determine if it would have altered any conclusions. 
1.4 Heterogeneity 
Heterogeneity is one of the most important issues which needs to be considered 
in a meta-analysis. Stedman's Medical Dictionary defines it as "heterogeneous 
state or quality."7 Thus being "composed of parts having various and dissimilar 
characteristics or properties." Heterogeneity in a meta-analysis may exist on two 
levels, clinical heterogeneity and statistical heterogeneity. 
1.4.1 Clinical Heterogeneity 
Clinical heterogeneity results from the differences in and the variability between 
individual studies compiled together in a meta-analysis. Individual studies are 
usually designed to answer a single clinical question, which is based on the 
primary endpoint, but there may also be secondary endpoints. Likewise, meta-
analysis attempts to answer specific questions using the data from those studies. 
Differences between the included studies can lead to clinical heterogeneity within 
a meta-analysis. Obvious sources of clinical heterogeneity are revealed when 
comparing patient characteristics, study centres, the intervention and the clinical 
endpoints used in the various studies. 
The patients enrolled in each study may differ in gender, age, comorbid 
illnesses and there may be difference in the results obtained from patients of 
different racial origins. We cannot assume that different therapies are equally 
effective in men and women. The gender issue has been quite relevant in many 
early cardiovascular studies interested in the effect of lipid lowering agents on 
decreasing coronary events in which the majority of patients were men8• Such 
studies limit the generalizability to the general population and combining studies 
with different gender mixes can also introduce clinical heterogeneity into the 
meta-analysis. 
Age is important in reviewing the effect of any intervention. Again, using 
cholesterol lowering agents as a typical example, there is an age related decrease 
in the risk of cardiovascular events with increasing age. Law et. al. found that a 
decrease of 0.6 mmol/L of serum cholesterol in men resulted in the following 
decreased risks of Ischemic Heart Disease (IHD) for the respective age group9: 
Table 1: Risk reduction of IHD with 0.6 mmol/L decrease in serum cholesterol 
Age 
40 
so 
60 
70 
80 
% reduced risk of IHD 
54 
39 
27 
20 
19 
Clearly, this is a single example, however it demonstrates that we may not be able 
to generalize the treatment effect observed on one age group to all age groups. 
Combining such groups can lead to clinical heterogeneity. 
Finally, racial difference may be a source of clinical heterogeneity as the 
effectiveness of therapies may vary between races. A very recent example of this 
was the difference in the efficacy of an HIV vaccination program on high-risk 
individuals. In that study, people of African origin were found to have reduced 
incidences of HIV acquisition after vaccination compared with those of Caucasian 
origin10• Clearly, combining the results obtained from studies conducted on single 
race with distinctly different subgroups will likely introduce heterogeneity when 
meta-analysis is performed. 
Thompson et. al. 11discussed underlying risk as a source ofheterogeneity in meta-
analysis in their paper. The authors explored the likelihood that there are inherent 
differences in patient populations for reaching the defined clinical endpoint. The 
likelihood of a treatment benefiting a higher risk individual may be much higher 
than in a lower risk individual. The authors used sclerotherapy for esophageal 
varices as an example and demonstrated heterogeneity is in fact introduced by 
combining patient populations with differing initial risk. Esophageal varices are 
graded according to size and high risk features such as a cherry red spot on a 
varix. Larger varices, those that occlude the esophageal lumen (Grade IV) and 
those with a "red spot" have the highest risk ofbleeding12• Smaller varices, 
approximately 5mm in size (Grade II) are at lower risk of bleeding. Combining 
studies which have a greater proportion of low risk patients with studies having a a 
greater proportion of high risk patients will almost certainly introduce 
heterogeneity. 
The intervention is typically the next source of clinical heterogeneity as there 
may be differences in the trial medication for different therapeutic trials. There 
may be differences in the dose used, the route administered (ie orally vs 
intramuscularly vs intravenously), the timing of drug administration or the 
duration in which the medication is given. When discussing intervention, it is also 
important to remember that there may be differences between medications being 
used within a class of drugs. There are numerous examples of meta-analyses using 
and combining classes of drugs such as different angiotensin converting enzyme 
inhibitors and/or angiotensin II receptor blockers13•14•15 • These two classes of 
medications which have numerous formulations that can be given one, two, three 
or even four times daily. It is not important to review the pharmacology of these 
medications at this time but it is important to acknowledge that there may or may 
not be a "class effect." Subtle differences betweeen medications may make one 
better than another. Therefore, combining these medications, which may 
potentially be given in different doses or by different routes, is an obvious 
potential source of clinical heterogeneity. 
The "class effect" also needs to be explored with regard to potential biochemical 
or physiologic effects within a group of medications. Beta- blockers are a large 
class of commonly used medications with different physiologic activity (ie non-
selective and cardioselective ). These differences may be important when 
evaluating different clinical endpoints. In cardiovascular studies, the physiologic 
differences between beta-blockers may not be as relevant as they are in 
Gastroenterology ( eg. prevention of variceal bleeding). Both non and 
cardioselective beta-blockers affect the heart but cardioslective beta-blockers have 
little to no effect on portal pressures within the portal venous system of the liver. 16 
Therefore, combining studies utilizing these medications, which may potentially 
be given in different doses or by different routes, or with different physiologic 
activity is an obvious potential source of clinical heterogeneity. 
The final potential source of clinical heterogeneity is in the definition of the 
clinical endpoint. For example, there is no way to dispute an endpoint such as 
mortality, however, not all endpoints are as clearly defined. A clear example of 
this is found within the Crohn' s disease literature where the definition of clinical 
response to therapy is often variable. Studies will often define clinical response 
and/or remission based on a scoring system referred to as the Crohn's disease 
activity index (CDAI). These studies often define remission as a CDAI of less 
than a score of less than150 and a response usually as a decrease ofbetween 50 
and 100 points17• Therefore, combining studies that are looking for a response to 
therapy as opposed to remission can lead to overestimation of the effect of an 
intervention and contribute to the heterogeneity between studies. 
1.4.2 Statistical Heterogeneity 
The degree of statistical heterogeneity is determined by a mathematical 
assessment of the variability between the studies combined in meta-analysis. 
Statistical heterogeneity may be caused by documented clinical differences or 
methodological differences between studies or possibly related to unknown or 
unrecorded trial characteristics18 • The imprecision of individual trials is 
demonstrated by their respective confidence intervals about the odds ratio. 
Subsequently, when combining multiple studies, there needs to be an assessment 
as to whether the variation in estimates of treatment effect between studies is 
greater than can be explained by chance alone. This is accomplished by 
calculating the Chi Square statistic in meta-analysis which is the test of 
homogeneity and then comparing studies visually. 
The Chi Square statistic for heterogeneity (lack of homogeneity) in meta-
analysis consists of the mathematical assessment of within study and between 
study variation between outcomes of the studies included in the systemic review. 
Heterogeneity exists if the Chi Square statistic is greater than the degrees of 
freedom(df= number of studies minus one)18•19•20• This test is very non-specific 
and lacks statistical power. Concluding that study outcomes are homogeneous 
because there is no statistical heterogeneity is not necessarily true. It is therefore 
necessary to examine the graphical presentation of outcomes. The concept of 
comparing studies visually is very simple. After plotting the odds ratios and their 
confidence intervals of each study on a standard meta-analysis graphical axis 
(Forest Plot), the upper and lower limits of the confidence intervals are compared. 
For homogeneous data it is expected that a single line can be drawn down through 
and intersecting the confidence interval of all studies (eg Fig.1)18• When the upper 
limit of a single study does not cross the lower limit of all other studies, this test of 
visual inspection will determine that heterogeneity is likely to exist (Fig.2). 
Identifying whether or not heterogeneity exists and the potential explanations for 
that heterogeneity are obviously important to the overall concept of meta-analysis. 
Dealing with it and deciding what to do if heterogeneity is present in a meta-
analysis is a more complex process. Purists argue that if heterogeneity exists, the 
data should not be combined in meta-analysis1•3•11 •18•19• However, the purpose of 
meta-analysis is that of pooling available studies to find the best estimate of the 
overall treatment effect. Therefore, if heterogeneity is present, it should not 
preclude statistical pooling with the Mantel-Haenszel test. Performing sensitivity 
analysis within the framework of the meta-analysis may provide the answers as to 
why heterogeneity exists17• Subgroup analysis is the process of pooling subgroups 
within the overall analysis to determine if the heterogeneity is resolved in the 
smaller subgroups. Combining subsets of studies with more similar characteristics 
such as study population, treatment, and outcomes may be more clinically 
homogeneous and allow for subgroup conclusions to be made. 
Meier argues, in his commentary on heterogeneity, that we are mostly looking for 
a quantitative effect rather than a qualitative effect when dealing with heterogenous 
studies20• If, as he states, there is a relatively common effect in all studies rather 
than a less uniform effect, then studies should be able to be pooled in meta-
analysis. If several studies with non-significant results all tend to favour a 
treatment but the Chi Square statistic suggests heterogeneity, Meier would continue 
with his analysis. Though he does not state it in his commentary, it would appear 
that he is indirectly referring to visually assessing Forest plots for heterogeneity. 
He acknowledges that experts such as Peto would argue against this statement. 
There is less support for the Meier argument and no other literature supporting his 
argument could be found. When the desired result is finding the best overall 
estimate of treatment effect, it seems to make less sense to not pool studies. 
Fig.l Schematic Illustration of homogeneity Visually 
pooled -~----• 
0 
Log Odds Ratio 
Fig.2 Schematic Illustration of heterogeneity Visually 
pooled ---1 
0 
Log Odds Ratio 
1.5 Publication Bias in Meta-Analysis 
Meta-analysis is a widely accepted research tool, however, there are limitations 
associated with the methodology. One of the most commonly cited problems with 
meta-analysis is publication bias. 
Publication bias refers to the possibility that "research with statistically significant 
results is more likely to be submitted and published than work with null or non-
significant results"21 • However, others have expanded publication bias in meta-
analysis to English language bias, multiple publication bias and paper selection bias. 
English Language bias refers to the meta-analysis reviewing only those papers 
published in English, thus eliminating many potential studies. Positive papers are 
also more likely to be presented in English journals. Papers may occassionally be 
submitted to more than one journal resulting in the small possibility that a given 
study is included more than once but multiple publication also increases the 
probabilty of discovering the study. Multiple publication bias should be avoided 
careful review of papers to rule out multiple publication. Paper selection bias refers 
to the likelihood that journal editors are more likely to publish papers which show a 
therapeutic advantage over papers which fail to display a benefit. The result of 
these potential biases is that inappropriate conclusions may be reached as a result of 
over-representation of published positive papers22• It is therefore possible that a 
potentially non-beneficial therapy could be assumed to be beneficial if only positive 
studies were included. 
Eggar and Smith have reviewed the potential sources of bias which are 
involved in meta-analysis23 • In their paper, they compared two meta-analyses, 
Leizorovicz et. al. 24 and Nurmohamed et. al., 25 that examined the role of low 
molecular weight heparin for prophylaxis of deep venous thrombosis in the post-
operative setting. The literature searches both covered the same time period, 1984-
91, but the authors selected somewhat different study inclusion criteria and the 
Nurmohamed et. al. study was limited to English only. Therefore, 39 and 23 studies 
were included respectively, yet only 18 studies were common to both meta-analyses. 
This simple example illustrates one of the concerns of those who critique meta-
analysis: how can we be certain that all possible data has been included in the 
analysis? 
Easterbrook et. al.21 wished to examine factors contributing to statistical 
significance and the effect of statistical significance on publication. After 
identifying 720 studies that were approved by the ethics department at Oxford 
University, they contacted the principal investigator of 487 studies. They queried: 
was the work completed? What were the results? Was it presented or published? 
Their study showed that statistically significant results had a direct effect on 
whether or not a study was published or presented at a major meeting. 
68% of published and presented studies had statistically 
significant results compared with only 65% of those published, 
55o/o of those presented and 29% of those neither published or presented. 
Conversely, only 15% of studies with statistically significant results remained 
unpublished or not presented compared with 44% of those with null results. 
The difference between being published or not based on statistical significance was 
significantly different using a Chi Square test. Moreover,"the mean citation index 
of the publishing journal was significantly higher for those studies with statistically 
significant results compared with non-significant results." 
There may be other causes for non-publication of a study other than lack of a 
statistically significant result. In the Easterbrook et. al. study, the principal 
investigator was asked if there was any reason for non-publication21 • Obtaining a 
null results was cited in over one and a half of instances as the reason for not 
writing a paper. However, pharmaceutical companies were blamed for non-
publication of results in 11% of cases because data was managed at the 
pharmaceutical company. Editorial rejection accounted for only 9% of non-
published studies. 
Joannidis examined the effect of statistical significance on the time to publication 
of randomized controlled trials sponsored by the National Institutes of Health in the 
field of the Human Immunodeficiency Virus26• He found that positive trials were 
submitted more rapidly than negative trials( 1 versus 1.6 years) and were published 
more rapidly after submission(0.8 versus 1.1 years). Therefore, at any point in time, 
a literature search is more likely to identify positive trials rather than negative trials 
thus contributing to the possibility of introducing publication bias. The only way 
that one could possibly retrieve more negative studies is if there had been many 
more negative than positive studies submitted. 
The probability of a study being published in a recognized journal is quite often 
affected by the language in which the paper is written or alternatively the country in 
which the paper had been published. For example, Gregoire et. al. identified 36 
meta-analyses published in leading English language medical journals and found 
that 26 of these had limited their search to English language only27• They then went 
on to search the German, Austrian and Swiss medical literature for articles 
published by lead authors included in any of the cited literature. Studies with 
significant results were more likely to be published in English. For example, 63o/o 
of studies with significant results were published in English versus 35% of studies 
published in German by the same authors. This resulted in the odds of English 
publication of3.8 for studies with statistically significant results. Thus, by 
excluding Non-English studies, there is significant bias introduced in favour of any 
therapeutic trial. 
Eggar and Smith also identify the impact of database bias as a subset of 
publication bias. We are unlikely to see the results of studies being done in 
developing countries because the journals in developing countries are not cited in 
medline or similar citation indexes23 • India, for example, has the highest research 
output of all developing countries and most journals are published in English. Yet, 
only 30 of its journals are indexed on Medline28• Therefore, this set ofresearch is 
effectively hidden from any researcher planning a meta-analysis. 
Thus far, the problems associated with adequately identifying research studies 
and how that causes publication bias have been discussed. However, it is also 
possible to introduce multiple publication bias. Studies with significant results are 
more likely to have multiple publications and presentations 21 • These studies are 
thus more likely to be identified in computer searches or cited by other researchers 
or reviewers. It is also possible that authors include data from the same group of 
patients in multiple studies. This effectively increases the likelihood of finding a 
statistically significant study compared to that of finding a negative study. Data 
which may be retrieved from studies with multiple publications could potentially be 
duplicated in the data presented in the meta analysis. These factors will usually lead 
to bias in favour of the therapeutic arm. 
Publication bias plays a major role in the delivery of clinical information to the 
medical community and to those who wish to perform meta-analysis. Because of 
this, methods to assess publication bias have been devised, including the assessment 
of funnel plots or the statistical manipulation of the data using a linear regression 
technique. 
A funnel plot is a graphical representation of effect estimates (taken from each 
study) plotted against the sample size29• Plots of studies avoiding publication bias 
should resemble an inverted funnel and the plots of studies with publication bias 
will appear asymmetrical30• Duval et. al.30 and Sutton et. al.31 have used a trim and 
fill method to assess whether or not publication bias was present. The assessment of 
asymmetry in funnel plots is often subjective and observers do not always agree on 
the appearance29• The trim and fill method examines the structure of the funnel plot 
specifically looking for asymmetry. Sutton et. al. showed asymmetry in 54% of 
reviews on the Cochrane database and stated that publication bias may be present in 
up to 50% of meta-analyses but is strongly indicated in 20%31 • 
However, the funnel plot can be modified using a linear regression technique. In 
this linear regression model, the standard normal deviate (SND), defined as the odds 
ratio divided by its standard error, is regressed against the estimate precision, the 
latter being defined as the inverse of the standard error. If there is symmetry within 
the funnel plot, the intercept of the SND will be zero. 
Eggar et. al. used the linear regression model to compare the results of meta-
analysis to subsequently published large randomized studies to test this model in 
prediction of whether or not publication bias existed29• They found that the 90o/o 
confidence interval around the SND intersected with zero in 4 of 4 concordant 
studies. That is, the direction and magnitude of effect as shown in the meta-analysis 
was similar to that of the large randomized study. Furthermore, the 90o/o confidence 
interval did not include zero in 3 of 4 discordant pairs (ie: the results of the meta-
analysis and the large randomized study differed in regard to the direction or size of 
the effect). 
It is important to attempt to determine whether or not publication bias exists. 
However, it is not possible to exclude publication bias by using either of the above 
mentioned methods. Sutton et. al. 31 did not test their trim and fill method in a 
manner similar to that ofEggar et. al. However, Eggar et. al. only compared the 
results of 8 meta-analyses to subsequent large randomized studies. He does not 
explain to us why he used the 90% confidence interval for the SND. If we examine 
the upper limit of the 90% confidence interval in the 3 pairs of studies with 
discordant results, we see that it is close to zero. The implications of drawing 
conclusions based on the comparison of 8 meta-analyses to 8 large randomized 
studies are paramount. In no other research field could we rely on such a small 
sample size. 
Eggar and his colleagues were criticized in a number of letters to the editor in 
BMJ. Stuck et. al. question whether the assymetry in funnel plots is due to 
publication bias, or, is it due to true heterogeneity32• Others point to the fact that the 
linear regression test had a 10% false positive rate which is higher than the standard 
acceptable level of 5% for a type 1 error. Clearly, there is no simple answer and no 
absolute way to ensure that publication bias has been avoided. 
1.6 Definition of Peptic Ulcer Disease 
Peptic ulcers are mucosal lesions in the stomach (gastric ulcer) or the duodenum 
(duodenal ulcer). Peptic ulcers occur as a result of a breakdown in the complex 
interaction between acid and digestive enzymes and the mucosal defence barrier35 • 
Clinically, they can present in several different ways with the most common being 
dyspepsia (upper abdominal pain, nausea or vomiting). Peptic ulcers can also 
present as a more complicated lesion such as bleeding, upper gastrointestinal 
obstruction or perforation. 35 
1. 7 Epidemiology of Upper Gastrointestinal Bleeding 
Bleeding from the upper gastrointestinal (UGI) tract is a common medical 
problem with significant morbidity and mortality. UGI bleeding accounts for 
approximately 100 admission per 100 000 population per yea~3•34 • Bleeding is most 
commonly secondary to peptic ulcer disease(PUD) which accounts for 
approximately 50% of those patients who undergo diagnostic endoscopl5• The 
morbidity from UGI bleeding is due to rebleeding, blood transfusion and emergency 
surgery. Mortality rates have been estimated to be as high as 14% but in more 
recent studies, the estimated mortality from bleeding secondary to PUD is 
approximately 4.1 %35•49• 
1.8 Risk ofReb1eeding 
Recurrent rebleeding from bleeding PUD is a significant problem and the rebleeding 
rate ranges from 5 to 65% depending on the clinical or endoscopic risk factors or 
both. 
1.8.1 Clinical Data to Predict Rebleeding 
Several investigators have examined the ability of clinical data to predict the 
probability ofrebleeding34•51-54• These studies consistently conclude that the clinical 
factors associated with an increased probability of rebleeding include hemodynamic 
instability and melena. The odds ratio for these factors when present is between 3 
and 6. As well, an elevated blood urea nitrogen was present in more patients who 
had rebleeding but it was not considered significant on logistic regression analysis34• 
Other demographic and laboratory data did not impact on the risk of rebleeding. 
The problem with using clinical factors to predict rebleeding is they have a low 
sensitivity. One study by Jaramillo concluded that shock, defined as a systolic 
blood pressure less than 100 mm Hg, was the strongest clinical predictor of 
rebleeding54• However, only 65 of312 patients who had rebleeding had shock 
(sensitivity=21 %) and 1161 of 1255 who did not rebleed did not have 
shock(specificity=93o/o). Thus, with a sensitivity of only 21%, it is quite obvious 
that even the strongest clinical predictor of rebleeding would be quite unsatisfactory 
to stratify patients into high or low risk of rebleeding. 
1.8.2 Endoscopic Signs to Predict Rebleeding 
The role of endoscopic assessment in the prediction of rebleeding in PUD has been 
clearly established 55• Various endoscopic features of ulcers have been examined, 
however, the features which consistently show high predictive value for recurrent 
haemorrhage are active bleeding (spurting or oozing), a non bleeding vessel 
(NBVV) and fresh clot in the ulcer base resistant to gentle washing. The odds ratio 
for rebleeding when either of these four endoscopic findings are present ranges 
between 3 and 1 7. Other features such as a black spot in the ulcer base and a clean 
ulcer base are of low predictive value. Laine has reviewed the studies which 
prospectively examined endoscopic findings as predictors of hemorrhage and these 
are summarized in Table 255 • Patients included in these studies did not have 
therapeutic endoscopy. Endoscopic predictors will identify approximately 85% of 
the patients likely to rebleed. 
Table 2: The prevalence of endoscopic features in PUD and the probability of 
further hemorrhage55 
Endoscopic Prevalence % (range) Further Bleeding% 
Characteristic (range) 
Clean base 42 (19-52) 5 (0-10) 
Flat spot 20 (0-42) 10 (0-13) 
Adherent clot 17 (0-49) 22 (14-36) 
NBVV 17 (4-35) 43 (0-81) 
Active bleeding 18 (4-26) 55 (17-100) 
1.8.3 Clinical Data and Endoscopic Signs to predict rebleeding 
Two authors have developed scoring systems which combine clinical data and 
endoscopic signs in attempt to characterize patients who were at highest risk of 
rebleeding33•51 • The first is referred to as the Baylor Bleeding Score51 • It considers 
age, the number of comorbid illnesses and whether these illnesses are acute or 
chronic to calculate a pre-endoscopy score. An endoscopy score is based on the 
bleeding stigmata associated with the ulcer whether or not it is on the posterior wall 
bulb. By combining the two scores, a post-endoscopy score is generated. The 
relevant data needed to calculate this score are summarized in Table 3. This score is 
used to divide patients into groups with high or low risks of rebleeding after 
therapeutic endoscopy has been performed based on the pre-endoscopy score or the 
post endoscopy score. A pre-endoscopy score of greater than 5 has a sensitivity of 
100% and a specificity of 74% in predicting rebleeding while a post-endoscopy 
score greater than 1 0 increases the specificity to 79%. Saeed 53 validated his 
bleeding score in a second prospective study of 100 patients with ulcer hemorrhage. 
Eight patients who had rebleeding in his study were labelled high risk and no 
patients labelled as low risk had subsequent bleeding. Therefore, he concluded that 
the Baylor Bleeding Score accurately identifies those patients at highest risk of 
rebleeding following therapeutic endoscopy. 
Table 3: Clinical scores in the Baylor Bleeding Score 
Assign Pre-Endoscopy Score Endoscopy Score 
Score Age #Illnesses Acuity 
0 <30 0 Clean base 
1 31-49 1-2 Clot 
2 50-59 
3 60-69 NBVV** 
4 3-4 Chronic PWB* Ooze 
5 >69 >5 Acute Spurt 
*PWB=posterior wall bulb, **NBVV=non-bleeding visible vessel 
Consider a 48 year old man (1 point) presenting with melena and a history of 
chronic bronchitis ( 1 +4=5 points). His pre-endoscopy score is 6 and thus has a high 
probability ofrebleeding on clinical criteria. If his endoscopy shows a clean base (0 
points), he could be safely discharged with therapy as his risk of further bleeding 
would be quite low (less than 5%) given a post endoscopy score of 6. However, 
active bleeding ( 4 or 5 points) would suggest that this man be admitted for 
monitoring as his post-endoscopy score would be 10 or 11 and his probabilty of 
rebleeding would be high. The post endoscopy score has more impact on younger 
patients as one can often change a patient from high risk based on clinical criteria as 
in the above case to a low risk as in this example. However, if the patient were 72 
( 5 points) with chronic congestive heart failure admitted with acute pancreatitis (3 
diseases = 4 points and acuity= 5 points: total score is 14), the endoscopy score 
would not be able to prevent the post endoscopy score from exceeding the high risk 
threshold of 1 0 points. 
The second scoring system which has been developed to assess the risk of 
rebleeding in PUD is called the Rockall Bleeding Score34• However, the Rockall 
Bleeding Score was not found to be useful in a prospective study by Vreeburg56 and 
coworkers in the prediction ofreb1eeding but did help predict mortality. 
1.9 Therapy of Bleeding Peptic Ulcer 
The management of bleeding PUD has evolved considerably over the past 3 
decades. The percentage of patients who require surgery and the mortality rate from 
bleeding have both significantly decreased. The major reason for the decline in 
these two rates has been the development of therapeutic endoscopic hemostasis56• 
Medical management of bleeding PUD has been directed primarily toward 
reducing gastric acidity. Two classes of pharmaceuticals broadly classified as 
histamine 2 receptor antagonists(H2RA) and proton pump inhibitors (PPI) have the 
ability to increase gastric pH and have been used in attempts to decrease the rates of 
rebleeding and mortality. The rationale for this approach is based on the fact that 
neither platelets nor the clotting cascade function optimally in the acidic 
environment of the UGI tract. Several investigators have examined the function of 
platelets and clotting factors under the influence of gastric contents59•60• The results 
of these studies consistently show that the low gastric pH renders platelet 
aggregation and the coagulation cascade ineffective. Furthermore, pepsin 
enzymatically degrades all of the clotting factors including fibrin, the end product of 
the clotting cascade. 
1.9.1 Therapeutic Endoscopy 
Therapeutic endoscopy involves applying a therapeutic modality directly to the 
site of active bleeding or to an ulcer base which appears to be at high risk of 
rebleeding. This may involve several different therapeutic options such as injection 
of either a sclerosant, epinephrine, saline, bipolar coagulation, heater probe therapy 
or laser therapy. The National Institute of Health consensus guidelines on 
therapeutic endoscopy in bleeding PUD recommends that all patients with arterial 
spurting, oozing or those who have a NBVV receive an endoscopic therapeutic 
modality61 • Therapeutic endoscopy is not necessary when a clean ulcer base or a 
pigmented spot is seen. Consideration should be given to removing a clot in the 
ulcer base that is resistant to gentle washing (this would allow the therapeutic 
endoscopist to apply therapeutics to the actual lesion). Several randomized 
controlled trials have investigated the different therapeutic modalities in bleeding 
PUD and their results have been systemically reviewed by two groups56•57• 
Two authors have analyzed the data on therapeutic endoscopy in bleeding PUD 
using meta-analysis and demonstrate similar results56•57• The meta-analysis by Cook 
and coworkers found a remarkable reduction in the rates of rebleeding, need for 
surgery and mortality regardless of the therapeutic method (laser, heater probe or 
injection) with an odds ratio of0.57, 0.37 and 0.40 respectively56• Benefits of 
therapeutic endoscopy were even more significant when lesions at higher risk of 
rebleeding were analysed. The odds ratios were 0.23 and 0.26 and 0.62 for the risk 
of recurrent bleeding, need for surgery and mortality respectively. In the subgroup 
analysis, no therapeutic method was found to give superior results to the other 
modalities. 
1.9.2 Histamine 2 Receptor Antagonists 
H2RA' s are a class of pharmaceuticals which have the ability to decrease acid 
production by chief cells in the gastric mucosa. No randomized controlled trial 
(RCT) has ever proven a benefit for H2RA over placebo in decreasing the rate of 
rebleeding or to decreasing mortality62•63 • In 1986, a meta-analysis of 26 RCT' s 
failed to show any benefit ofH2RA over placebo62• However, there was a small 
benefit in the reduction of rebleeding in the gastric ulcer subgroup. Subsequently, a 
large RCT of involving 1005 patients who were at very high risk of rebleeding 
based on endoscopic criteria also failed to display any benefit of famotidine over 
placebo63 • 
1.9.3 Proton Pump Inhibitors 
Proton Pump Inhibitors (PPis) are a second class of pharmaceuticals and include 
omeprazole, lansoprazole, esomeprazole, rabeprazole and pantoprazole. PPI's are 
more potent acid suppressors than H2RA' s. PPI' s get absorbed into the chief cells at 
the basal surface of the gastric parietal cell and bind irreversibly to the "proton 
pump," an active hydrogen-potassium exchange pump. This pump uses ATP energy 
to actively exchange potassium cations for hydrogen cations on the basal surface of 
the parietal cell. The hydrogen cation is then secreted into the gastric lumen which 
acidifies the gastric lumen. 
The first RCT using omeprazole in an attempt to reduce the rate of recurrent 
bleeding was in 199243• It included UGI bleeding from all potential causes but 
failed to show any benefit in favour of omeprazole in the PUD subgroup. Since 
then several RCT' s have been published with varying results36-42• There has been no 
consensus as to the benefit of PPI' s to prevent rebleeding or death in bleeding 
peptic ulcer. One such study carried out on India and published by Khuroo38 was 
heavily criticized. This study was a randomized double blind placebo controlled 
trial of high dose oral omeprazole which included patients with endoscopic criteria 
placing them at high risk of rebleeding. There was a very significant reduction in 
rebleeding and the need for surgery in the omeprazole group and no difference in 
mortality. The major problem with this study is that therapeutic endoscopy was not 
performed on any patients in this study while it is the standard of care in North 
America61 • 
2.0 Objective 
The purpose of this study is to systemically review the results of published RCT' s 
to better define the role ofPPI's in bleeding PUD. The primary endpoints chosen 
were rebleeding and overall mortality. Subgroup analysis was planned to examine 
the effect of therapeutic endoscopy on both rebleeding and mortality. Other 
analyses were planned for infusional PPI and bolus PPI compared with placebo for 
both rebleeding and mortality. 
3.0 Methods 
3.1 Selection of Topic 
The therapeutic use of proton pump inhibitors in bleeding peptic ulcer disease 
(PUD) lends itself well to meta-analysis. The selection of this topic is based on 
several factors. First, bleeding PUD is a common disorder causing significant 
morbidity and mortality. Prior to the introduction of proton pump inhibitors as acid 
suppressing medication, histamine receptor antagonists such as ranitidine were the 
most important acid suppressors, yet, their use did not reduce either morbidity or 
mortality in peptic ulcer bleeding. Since then, many studies examining the effect of 
proton pump inhibitors on bleeding from PUD have been published. It was initially 
a study from India38 which made us consider performing a systematic review on the 
topic. 
3 .2 Literature Search 
The literature review was begun by carrying out a computer search using the 
search engine PubMed. Pubmed is a recognized search engine provided free of 
charge on the internet by the National Library of Medicine in the USA. The goal of 
the search is to identify as many relevant studies as possible and therefore the 
following key words were utilized and cross referenced: 
1. omeprazole or pantoprazole or lansoprazole or esomeprazole or rabeprazole or 
proton pump inhibitor. This selection of terms allows us to select the group of 
PPI's currently in use thus ensuring that all members of the class have been 
included. The linkage term "or" expands the search so that all of the terms will 
be included. 
This was then linked to the following using the cross-linking Boolean "and". Using 
"and" for cross-linking selects studies which include all the terms. of interest. 
2. rebleeding or mortality. These are the main clinical endpoints of interest. 
3. peptic ulcer or non-variceal. Many published studies on upper GI bleeding have 
differentiated between variceal and non-variceal rather than peptic ulcer bleeding. 
Therefore, by including non-variceal, studies which may have had a subgroup of 
peptic ulcer will not be missed. 
4. randomized controlled trial or clinical trial. By using these we hope to help the 
screening process by eliminating observational type studies. 
English Language was not pre-selected as an exclusionary tool. Foreign Language 
studies were to be retrieved and translated. 
The references from relevant studies were reviewed to identify any further 
published studies. Occasionally, some authors may have had knowledge of other 
relevant studies and cited those. These were also included in the systematic review 
Finally, Index Medicus continues to reference published medical studies and it 
was also reviewed for the appropriate time period using the terms included in the 
medline search. Paper searching continues to be the most time consuming part of 
meta-analysis, however, searching Index Medicus helps to ensure no relevant studies 
have been excluded. Meeting abstracts were not reviewed because sensitivity 
analysis with abstracts included was not considered in the original plan of this thesis. 
3.3 Inclusion/Exclusion Criteria 
To be included in the analysis, studies needed to be prospective and 
randomized with an adequately identified control group (either placebo or H2RA). 
H2RA were considered an adequate control group because they have not been shown 
to have an overall significant benefit when compared to placebo62"63 • The treatment 
protocols had to identify the timing, route and dose of the specific medications 
given. Outcomes had to include the endpoints rebleeding and/or mortality. Only 
papers published in full were considered. Studies appearing as abstracts do not 
provide detailed methodology to fully determine whether or not they should be 
included in the analysis. Retrospective studies and historical control studies were 
excluded because they do not constitute an adequate control group and definition of 
clinical endpoints has to be determined retrospectively. 
3.4 Qualitative Analysis 
The data from papers meeting the inclusion criteria were assessed. The quality 
of published studies was assessed using a modification of the protocol developed by 
Chalmers et al.64• This assessment placed major importance on randomization and 
blinding. Other extracted information included: 
1. Definition of the study population. Where were the patients recruited from, as in 
were they seen in the emergency room, or were they already in the hospital with 
prior illnesses, demographics of the study population. 
2. Whether or not therapeutic endoscopy was performed. Studies not adhering to 
the National Institute of Health's guidelines on therapeutic endoscopy61 were 
considered not to have performed therapeutic endoscopy. It was decided after 
discussion that if a study performed therapeutic intervention only on a subgroup 
of patients which technically should all have received therapeutic endoscopy, that 
study would then be sub-grouped with studies not performing therapeutic 
endoscopy. 
3. Medication used, route given and the doses for the study. It was anticipated that 
several different PPis would be utilized and they may be given by alternate 
routes. Therefore, it was planned to gather this data prior to carrying out any 
analysis so that if subgroups needed to be examined, the data_ would be prepared. 
4. Single or multi-centered. Although the data collected from single or multi-
centered studies is not treated any differently in meta-analysis, multi-centered 
studies have the advantage and may in fact supply better quality data as there are 
fewer opportunities to introduce investigator bias based on well developed 
protocols. However, there is also the possibility having more variability in the 
administration of the protocols as well. 
5. Definition ofrebleeding. The definition ofrebleeding was considered appropriate 
if it included: recurrent hematemesis with fresh blood or fresh blood up a 
nasogastric tube, recurrent melena with a change in hemodynamic status defined 
by an increase in heart rate by 1 0 beats per minute or a drop in systolic blood 
pressure to 1 00 mm Hg (after the patient had been stabilized hemodynamically), 
or a drop of 20 giL in hemoglobin over a 24 hour period. Rebleeding could also 
include active bleeding at the time of repeat endoscopy. Coffee ground emesis 
(sometimes defined as hematemesis) was not considered to be active rebleeding 
unless it was associated with one of the above. 
3.5 Data Extraction 
Data was extracted independently by 2 reviewers (DS and JF). This included the 
number of experimental and control subjects and the number of subjects in each 
group who had rebleeding or who died. These data were collected on standardized 
forms in 2X2 tables. There were no discrepancies. 
3.6 Quantitative Analysis 
Rebleeding and mortality were considered the two primary analyses in this meta-
analysis. Data were collected for both endpoints as described above for both the 
treatment (PPI group) or control medication (placebo or H2RA). It was planned to 
pool all studies initially and then to perform meta-analysis on selected subgroups. 
Subgroups were identified prior to retrieving data and included: 
1. Therapeutic endoscopy. One of the major criticisms of the study which sparked 
interest in this meta-analysis was that therapeutic endoscopy had not been 
performed in what would be considered high risk patients. These concerns were 
initially raised at a journal club for Medical Residents at Memorial University by 
one of the staff Gastroenterologists. Therefore, it was felt that this would be an 
important subgroup of patients to see if those concerns and criticisms were 
founded. 
2. Dose of the medication given and whether it was administered as a bolus or 
infusion. It was not known whether there was an optimal dose ofPPI to be given 
or whether it should be given by bolus injection or by a continuous infusion. 
The Rev Man statistical software package (as supplied by the Cochrane 
Collaboration, http://hiru.mcmaster.ca/cochrane/) was used to perform the statistical 
analysis. Data was entered in simple 2x2 tables identifying the control and 
experimental groups. After identifying which studies were to be included in each 
analysis, these were pooled and the output recorded. The statistical package 
calculated the odds ratios and 95% confidence intervals for each study and then 
pooled the data. The Peto-method with a fixed effects model was selected to 
calculate the pooled odds ratio's and 95% confidence interval. 
Homogeneity was assessed both visually and with the Chi square test of 
homogeneity. Heterogeneity is discussed extensively in the introduction. The Chi 
Square statistic is calculated by the RevMan software. 
Publication bias, which was discussed extensively in the introduction, was also 
assessed. This was assessed using the funnel plot method and also the linear 
regression of the funnel plot method. The Stata statistical software package was 
used to perform funnel plots and linear regression. 
The number needed to treat (NNT) was calculated by taking the reciprocal of the 
difference between the bleeding rate in the control and treatment groups. 
4.0 Results 
4.1 Literature Search 
The literature search identified 60 studies. 43 of these were excluded because they 
were letters, reviews or did not relate specifically to the topic. The remaining 17 
studies were reviewed35-49• Two of these were excluded from the analysis. One 
because it used historical controls,66 the other because it's endpoint was successful 
control of hemorrhage as shown by repeat endoscopy on day 4 44• 
4.2 Qualitative Analysis 
The 15 studies included in the meta-analysis are summarized in Table 4. All 
studies used rebleeding as a major endpoint while 12 also included mortality data. 
Only 5 studies were double blind. Five studies37•39•40•46•50 did therapeutic endoscopy 
in all patients according to the National Institute of Health guidelines61 while another 
study performed therapeutic endoscopy on only patients with Forrest IA (defined as 
arterial spurting from the ulcer base) bleeding42 • This last study was grouped with 
those not performing therapeutic endoscopy according to the NIH guidelines. 
T bl 4 St d" fP t P I h"b"t . Bl d" P f Ul a e . u 1es o ro on ump n 1 1 ors m ee mg ep11c cer . 
Author Study Population Desi2n Medication/route 
Daneshmend All with UGI bleeding Randomized before Endo 
No specific criteria Single Centre - Blinded & no TE IV-Om (80 &40 TID) 
PUD subgroup vs Pl 
Lin-1 Endoscopic high risk bleeding PUD Randomized after Endo IV -Om ( 40& 160int) 
Forrest la-b & Ila Single Centre- Not Blinded & all TE vs Cim (300 and 1600) 
Lin- 2 Endoscopic high risk bleeding PUD Randomized after Endo IV -Om ( 40od or bid) 
Forrest lla Single Centre - Not Blinded & no TE vs Cim (300 q6h) 
Khuroo Endoscopic high risk bleeding PUD Randomized after Endo PO-Om ( 40 bid) 
Forrest la-b & Ila-b Single Centre- Blinded & noTE vs PI 
Schaffalitzky Endoscopic high risk bleeding PUD Randomized after Endo IV -Om (80 &8 mg/h) 
Forrest la-b & Ila-b & 2/3 of Multi-Centre- Blinded & all TE vs PI 
SBP<IOO HR.>IOO, orHgb<7 
Lanas Endoscopic high risk bleeding PUD Randomized after Endo IV -Om (80 &40 bid 
Forrest lb & Ila-b Sin_gle Centre not Blinded & no TE vs Ran( 50 q4h) 
Villanueva Endoscopic high risk bleeding PUD Randomized after Endo IV -Om (80 &40 bid) 
Forrest la-b Single Centre not Blinded & all TE vs Ran (50 q6h) 
Hasselgren Endoscopic high risk bleeding PUD Randomized after Endo IV-Om (80 & 8mg/h) 
-Forrest la-b & Ila-b Multi-Centre - Blinded vs PI 
All pts > 60 yrs TE in F-la only 
Orti Endoscopic high risk bleeding PUD Rahdomized after Endo IV -Om (80 &40 tid) 
Forrest lb & lla-b Single Centre not Blinded & no TE vs Ran (50 q6h) 
Uribarrena Not all Endoscopic high risk and Randomized after Endo IV -Om (80 &40 bid) 
207/282 PUD Single Centre not Blinded & noTE vs Cim (1200int) 
77/207 Forrest la-b or Ila 
Michel Endoscopic high risk bleeding PUD Randomized after Endo PO-Lans (30 bid) 
Forrest la-b & Ila-b Multi-Centre not Blinded & no TE vs Ran (300 bid) 
Prassler Endoscopic high risk bleeding PUD ?Randomized after Endo IV -Om (80 &40 tid) 
Forrest lb & Ila-b Single Centre not blinded & all TE vs Ran (50 &100q6h) 
Flores Endoscopic high risk bleeding PUD Randomized after Endo IV ·Om (80 &40 tid) 
Forrest lb & Ila-b Single Centre not Blinded & no TE vs Ran (50 &100a6h) 
Brunner Endoscopic high risk bleeding PUD Randomized after Endo IV -Om (80 int) 
Forrest Ib & Ila-b Single Centre not Blinded & no TE vs Ran ( 400 int) 
All patients in ICU & severely ill 
Lau Endoscopic high risk bleeding PUD Randomized after Endo IV -Om (80 & 8mglh) 
Forrest la-b & Ila Single Centre, Blinded & all TE VsPl 
PUD = peptic ulcer disease, TE = therapeutic endoscopy, IV = intravenous, PO = per oral, Om = omeprazole, Ran = 
ranitidine, Cim = cimetidine, Lans = lansoprazole and Pl = placebo, inf = infusion 
4.3 Statistical Analysis 
4.3.1 Rebleeding 
Combining the 15 studies which examined rebleeding shows a statistically 
significant benefit ofPPI versus either placebo or H2RA with a pooled odds ratio of 
0.55 (95% CI: 0.46- 0.66)(Fig. 3). There was statistical heterogeneity (Chi Square= 
42, df=15) between studies. Three studies had either upper or lower limits of their 
respective 95% CI which did not intersect with either the upper or lower limit of the 
remaining 12 studies36•43•46• Re-analyzing the data without two of these studies did 
not alter the pooled odds ratio36•43 (Fig.4) The rationale to exclude these studies and 
to re-analyze the data was based on the fact that the entry criteria for these two 
studies were significantly different than the enrollment criteria for the others. The 
Brunne~6 study used what should be considered the highest risk patients (see 
description of Baylor Bleeding Score in the introduction) for enrollment as these 
included patients already admitted to an intensive care unit with other unrelated 
illnesses36• The Daneshmend study, however, used lower risk patients, in that 
patients were enrolled prior to endoscopy and many of these would have had a low 
risk of rebleeding according to the endoscopic appearance of the ulcer42• The 
remaining 13 studies were more homogeneous in the type of patient recruited into 
the study. No explanation could be given as to why the Prassler study seemed to be 
an outlier. 
The pooled odds ratio when the experimental drug was given without therapeutic 
endoscopy was 0.54 (0.43 - 0.67)(Table 5) while it was 0.58 (0.42- 0.79) when 
therapeutic endoscopy was performed (Table 5). The pooled odds ratio remained 
significant regardless of the dose of medication used (studies were divided based on 
whether they gave 80 mg ofPPI per day or more than 80mg). However, there was a 
significant difference in favor of a reduction of rebleeding when the PPI was given 
as an infusion rather than as bolus injections (studies which used oral PPI38•47 were 
excluded from this analysis because the comparison involved only intravenous 
formulations ofPPI). The pooled odds ratio was 0.40 (0.29- 0.53) for infusion 
therapy while it was 0.82 (0.63- 1.07) for the group receiving bolus therapy. 
The number of patients required to be treated with PPI to prevent one further 
episode ofrebleeding ranged from 5.8 to 13.8 (Table 5) depending on the dose of 
PPI, the manner in which it was given and whether or not therapeutic endoscopy had 
been performed. 
F'~· ~ • Overall Rebleeding 
Citation EffectName Yea Treated Control Effect Lower Upper NTotal PValue 
Brunner Rebleeding 3/19 17/20 .03 .01 .19 39 .00 1---
Oaneshmend Rebleeding 58/246 70/257 .82 .55 1.23 503 .35 
Flores Rebleeding 2/38 8/43 .24 .05 1.23 81 .07 
Hasselgren Rebleeding 51/159 75/163 .55 .35 .87 322 .01 
Khuroo Rebleeding 12/110 40/110 .21 .10 .« 220 .00 
Lanas Rebleeding 6/28 9/23 .42 .12 1.45 51 .17 
Lau Rebleeding 5/120 24/120 .17 .06 .47 240 .00 
Lin-1 Rebleeding 2/50 12/50 .13 .03 .63 100 .00 
Lin-2 Rebleeding 4/26 5/13 .29 .06 1.36 39 .11 
Michel Rebleeding 8/38 11/37 .63 .22 1.80 75 .39 
Orti Rebleeding 11/252 15/267 .77 .35 1.70 519 .51 
Prassler Rebleedlng 30/106 33/126 1.11 .62 1.99 232 .72 
S chaffalitzky Rebleeding 20/134 37/140 .49 .27 .89 274 .02 
Uribarrena Rebleeding 6/131 6/151 1.16 .36 3.69 282 .80 
Villanueva Rebleedlng 13 I 45 11 I 41 1.11 .43 2.85 86 .83 
Fixed Combined (15) 231/1502 373/1561 .57 .47 .70 3063 .00 --+-
Random Combined (15) 231/1502 373/1561 .47 .32 .69 3063 .00 
---
0.1 0.2 0.5 1 2 5 10 
Favors PPI Favors Control 
,::-, s. 't ' Rebleeding Excluding Outliers •
Citation EffeetName Yea Treated Control Effect Lower Upper NTotal PValue 
Flores Rebleeding 2/38 8/43 .24 .05 1.23 81 .07 
Hasselgren Rebleeding 51/159 75/163 .55 .35 .87 322 .01 
Khuroo Rebleeding 12/110 40/110 .21 .10 .44 220 .00 
Lanas Rebleeding 6/28 9/23 .42 .12 1.45 51 .17 
Lau Rebleeding 5/120 24/120 .17 .06 .47 240 .00 
Lln-1 Rebleedlng 2/50 12/50 .13 .03 .63 100 .00 
Lln-2 Rebleeding 4/26 5/13 .29 .06 1.36 39 .11 
Michel Rebleedlng 8/38 11/37 .63 22 1.80 75 .39 
Ortl Rebleedlng 11/252 15/267 .77 .35 1.70 519 .51 
Prassler Rebleedlng 30/106 33/126 1.11 .62 1.99 232 .72 
SctiillfaiHzky Rebleeding 20/134 37/140 .49 .27 .89 274 .02 
Unbarrena Rebleeding 6/131 6/151 1.16 .36 3.69 282 .80 
-x_;tt.5 Villanueva Rebleeding 13/45 11/41 1.11 .43 2.85 86 .83 
Fixed Combined (13) 170/1237 286/1284 .64 .43 .67 2521 .00 
Random Combined (13) 170/1237 286/1284 .49 .34 .72 2521 .00 
0.1 0.2 0.5 1 2 5 10 
,Favors PPI Favors Control 
P~-~.· Rebleeding Without Therapeutic Endoscopy 
Citation EffectName Yea Treated Control Effect Lower Upper NTotal PValue 
Brunner Rebleeding 3/19 17/20 .03 .01 .19 39 .00 -
Daneshmend Rebieedlng 58/246 70/257 .82 .55 1.23 503 .35 
Flores Rebleedlng 2/38 8/43 .24 .05 1.23 81 .07 
Hasselgren Rebleeding 51/159 75/163 .55 .35 .87 322 .01 
Khutoo Rebleeding 12/110 40/110 .21 .10 .44 220 .00 
Lanas Rebleedlng 6/28 9/23 .42 .12 1.45 51 .17 
lin-2 Rebleedlng 4/26 5/13 .29 .06 1.36 39 .11 
Michel Rebleeding 8/38 11/37 .63 .22 1.80 75 .39 
Orti Rebleeding 11/252 15/267 .77 .35 1.70 519 .51 
Uribarrena Rebleeding 6/131 6/151 1.16 .36 3.69 282 .80 
Fixed Combined (10) 161/1047 256/1084 .54 .43 .68 2131 .00 -+-
Random Combined (10) 161/1047 256/1084 .46 .29 .72 2131 .00 
0.1 0.2 0.5 1 2 5 10 
Favors PPI Favors Control 
F~~ ~ ~ Rebleeding After Therapeutic Endoscopy 
Citation Effect Name Yea Treated Control Effect Lower Upper NTotal PValue 
Lau Rebleeding 5/120 24/120 .17 .06 .47 240 .00 
Lin-1 Rebleedlng 2/50 12/50 .13 .03 .63 100 .00 
Prassler Rebleedlng 30/106 33/126 1.11 .62 1.99 232 .72 
Schaffalitzky Rebleedlng 20/134 37/140 .49 .27 .89 274 .02 ~'1--;~ Villanueva Rebleedlng 13/45 11/41 1.11 .43 2.85 86 .83 
Fixed Combined (5) 70/455 117/477 .61 .43 .86 932 .01 
Random Combined (5) 70/455 117/477 .48 .21 1.08 932 .08 
0.1 0.2 0.5 1 2 5 10 
Favors PPI Favors Control 
F~ ~ :=1 • Rebleeding Infusion PPI 
CHatlon EffectName Yea Treated Control Effect Lower Upper NTotal PValue 
Brunner Rebleeding 3/19 17/20 .03 .01 .19 39 .00 
Hasselgren Rebleeding 51/159 75/163 .55 .35 .87 322 .01 
Lau Rebleeding 5/120 24/120 .17 .06 .47 240 .00 
Lin-1 Rebleeding 2/50 12/50 .13 .03 .63 100 .00 x;,~ Schaffalitzky Rebleeding 20/134 37/140 .49 .27 .69 274 .02 Fixed Combined (5) 81/482 165/493 .40 .29 .56 975 .00 
Random Combined (5) 81/482 165/493 .24 .11 .55 975 .00 
0.1 0.2 0.5 1 2 5 10 
Favors PPI Favors Control 
Rebleeding Bolus PPI 
Citation ElfectName Yea Treated Control Effect Lower Upper NTotal PValue 
Daneshmend Rebleeding 58/246 70/257 .82 .55 1.23 503 .35 
Flores Rebleeding 2/38 8/43 .24 .05 1.23 81 .07 
Lanas Rebleeding 6/28 9/23 .42 .12 1.45 51 .17 
Lin-2 Rebleeding 4/26 5/13 .29 .06 1.36 39 .11 
Orti Rebleeding 11/252 15/267 .77 .35 1.70 519 .51 
Prassler Rebleeding 30/106 33/126 1.11 .62 1.99 232 .72 
Uribarrena Rebleedlng 6/131 6/151 1.16 .36 3.69 282 .80 
Villanueva Rebleedlng 13/45 11/41 1.11 .43 2.85 86 .83 
Fixed Combined (8) 130/872 157/921 .83 .63 1.08 1793 .16 
-
Random Combined (8) 130/872 157/921 .83 .63 1.08 1793 .16 
-
0.1 0.2 0.5 1 2 5 10 
Favors PPI Favors Control 
Table 5: Results of Subgroup analysis and the Number Needed 
to Treat 
Endpoint Number Sample Pooled OR 95°/o CI NNT 
of studies Size 
Rebleeding 15 3063 0.55 0.46- 0.66 11.7 
Rebleeding - no TE 10 2131 0.58 0.46-0.73 12.2 
Rebleeding - TE 5 932 0.69 0.48-0.99 11.1 
Rebleeding - Inf 5 975 0.40 0.29- 0.53 5.8 
Rebleeding - bolus 8 1793 0.82 0.63- 1.07 N/A 
Rebleeding - 80 mg 7 792 0.39 0.27- 0.57 8.3 
Rebleeding - >80 mg 8 2271 0.61 0.50- 0.76 13.8 
Mortality 12 2910 1.32 0.90- 1.94 N/A 
Mortality -no TE 7 1978 1.52 0.94-2.46 NIA 
Mortality - TE 5 932 0.77 0.45-1.33 N/A 
TE = Therapeutic Endoscopy 
Inf = Infusion 
Nl A = Not Applicable 
4.3 .2Mortality 
Pooling the 12 studies which provided mortality data showed no statistical 
difference in mortality between the experimental and control groups with a pooled 
odds ratio (95% CI) of 1.13 (0.79 -1.62)(Fig. 9). There was no statistical 
heterogeneity. Subgroup analysis revealed differing results based on whether or not 
therapeutic endoscopy was performed. There was a trend toward a reduction in 
mortality when PPI's were given after therapeutic endoscopy with a pooled odds 
ratio was 0.77 (0.45- 1.33){Table 5). In contrast there was a trend toward an 
increased mortality in those studies in which therapeutic endoscopy was not 
performed with a pooled odds ratio of 1.52 (0.94 - 2.46) {Table 5). There was no 
heterogeneity in the therapeutic endoscopy subgroup, however, there was significant 
heterogeneity in the subgroup of studies not performing therapeutic endoscopy. 
There were no significant differences in mortality in the other subgroups of patients. 
F\~. ~ • Overall Mortality , 
Citation EffectName Yea Treated Control Effect Lower Upper NTotal PValue 
Daneshmend Mortality 23/246 13/257 1.94 .96 3.91 503 .06 
Flores Mortality 0/38 0/43 1.13 .02 58.32 81 .95 
Hasselgren Mortality 11/159 1/163 12.04 1.54 94.40 322 .00 
Khuroo Mortality 2/110 6/110 .32 .06 1.63 220 .15 
Lanas Mortality 2/28 2/23 .81 .10 6.23 51 .84 
Lau Mortality 5/120 11/120 .43 .14 1.28 240 .12 
Lin-1 Mortality 0/50 2/50 .19 .01 4.10 100 .24 
Orti Mortality 2/252 2/267 1.06 .15 7.58 519 .95 
Prassler Mortality 6/106 6/126 1.20 .38 3.84 232 .76 
Schaffalitzky Mortality 10/134 11/140 .95 .39 2.31 274 .90 
Uribarrena Mortality 2/131 5/151 .45 .09 2.37 282 .34 
't. X::: ,-z 
Villanueva Mortality 3/45 1/41 2.86 .29 28.62 86 .35 
Fixed Combined (12) 66/1419 60/1491 1.09 .74 1.60 2910 .68 - :--
0.1 0.2 0.5 1 2 5 10 
Favors PPI Favors Control 
Mortality Without Therapeutic Endoscopy 
Citation EffectName Yea Treated Control Effect Lower Upper NTotal PValue 
Daneshmend Mortality 23/246 13/257 1.94 .96 3.91 503 .06 
Flores Mortality 0/38 0/43 1.13 .02 58.32 81 .95 
Hasselgren Mortality 11 /159 1/163 12.04 1.54 94.40 322 .00 
Khuroo Mortality 2/110 6/110 .32 .06 1.63 220 .15 
Lanas Mortality 2/28 2/23 .81 .10 6.23 51 .84 l·b Ortl Mortality 2/252 2/267 1.06 .15 7.58 519 .95 Fixed Combined (6) 40/833 24/863 1.58 .90 2.76 1696 .11 
Random Combined (6) 40/833 24/863 1.41 .55 3.61 1696 .48 
0.1 0.2 0.5 2 5 10 
Favors PPI Favors Control 
r~~~11 I Mortality After Therapeutic Endoscopy 
Citation EffectName Yea Treated Control Effect Lower Upper NTotal PValue 
Lau Rebleeding 5/120 24/120 .17 .06 .47 240 .00 
Lin-1 Mortality 0/50 2/50 .19 .01 4.10 100 .24 
Prassler Mortality 6/106 6/126 1.20 .38 3.84 232 .76 
Schaffalitzky Mortality 10/134 11/140 .95 .39 2.31 274 .90 
Villanueva Mortality 3/45 1/41 2.86 .29 28.62 86 .35 1~ i·~ Fixed Combined (5) 24/455 44/477 .60 .35 1.05 932 .07 
Random Combined (5} 24/455 44/477 .65 .22 1.88 932 .42 
0.1 0.2 0.5 2 5 10 
Favors PPI Favors Control 
Mortality - PPI Infusion 
Citation EffectName Yea Treated Control Effec Lowe Uppe NTotal PValue 
Hasselgren Mortality 11/159 1/163 12.04 1.54 94.40 322 .00 
Lau Mortality 5/120 11/120 .43 .14 1.28 240 .12 
Un-1 Mortality 0/&J 2/&J .19 .01 4.10 100 .24 
Schaffalitzky Mortality 10/134 11/140 .95 .39 2.31 274 .90 
Fixed Combined (4) 26/463 25/473 .86 .45 1.63 936 .64 ~~ Random Combined (4) 26/463 25/473 1.02 .25 4.08 936 .98 
0.1 0.2 0.5 1 2 5 10 
Favors PPI Favors Control 
2 5 10 
Favors Control 
~~cs.-14: 
Mortality After Therapeutic Endoscopy with PPI Infusion 
Citation EffectName Yea Treated Control Effect Lower Upper NTotal PValue 
Lau Mortality 5/120 11/120 .43 .14 1.28 240 .12 
·I 
Lin-1 Mortality 0/50 2/50 .19 .01 4.10 100 .24 
Schaffalitzky Mortality 10/134 11/140 .95 .39 2.31 274 .90 
Fixed Combined (3) 15/304 241310 .65 .33 1.27 614 .21 
Random Combined (3) 15/304 241310 .65 .33 1.27 614 .21 
0.1 0.2 0.5 2 5 10 
Favors PPI Favors Control 
4.4 Publication Bias 
Funnel plots were performed using two methods, both of which yielded identical 
results. Figures 15 and 16 plot the standard error and precision by effect size for 
rebleeding data respectively. The graphical presentation shows several studies lying 
outside the boundary of the triangle and the inverted funnel for their respective plots. 
Figure 15, which plots precision of the Log Odds ratio (defined by the reciprocal of 
the standard error of each study) against the Log Odds Ratio identified 8 of 15 
studies outside the boundaries of the inverted funnel. Similarly, Figure 16 displayed 
nearly identical results as only 4 studies fully lie inside the triangle. Therefore, it is 
quite likely that publication bias exists in the publication of studies examining the 
effect of PPI therapy of upper GI bleeding. If there were as few as 4 small negative 
studies not published, the funnel plot for figure 15 would be quite symmetrical. 
Funnel plots for the standard error and precision by effect size were also plotted for 
the mortality data. These are presented in Figures 17 and 18 respectively. Both 
figures identified 4 full studies lying outside the boundaries of the triangle and 
inverted funnel. This points to the existence of publication bias in the mortality data 
as well. 
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5.0 Discussion 
5.1 Interpreting the Results 
The goal of treatment for patients with UGIB from PUD is the prevention of 
further bleeding. The results ofthis systematic review of 15 studies with a total 
sample size of approximately 3000 patients indicates that therapy with PPI in high 
risk patients with bleeding PUD (Forrest I- II) is beneficial with a significant 
reduction in the rebleeding rate. The benefit ofPPI therapy in the prevention of 
rebleeding persisted regardless of whether or not therapeutic endoscopy had been 
performed. There is added benefit to giving intravenous PPI's as an infusion rather 
than as bolus injections, given the lack of a significant benefit in the bolus subgroup. 
Yet, two studies included in this systematic review used oral PPI, one demonstrating 
a significant benefie8 in favor of PPI and the other44 showing no benefit. The 
optimal dose of PPI for a high risk bleeding peptic ulcer is yet to be determined as 
there was no difference in the reduction of rebleeding when the 80 mg doses were 
compared to more than 80 mg. 
It has long been speculated that control of acid output from the stomach would 
help to reduce the rate of recurrent bleeding. In-vitro studies clearly demonstrate 
that neither the fibrin plug nor the platelet clot is stable at the low pH found in the 
normal stomach59•60• Brunner has shown that an infusion ofPPI after an initial bolus 
provided more control of acid output and prevented decreases in pH relative to bolus 
injections in normal subjects65 • It is not surprising then that the subgroup analysis of 
PPI infusion compared with the control group had the most significant reduction in 
rebleeding with a NNT of only 6. The PPI bolus subgroup analysis was the only 
subgroup which failed to demonstrate a benefit over the control medication for the 
prevention of rebleeding. This further supports the conclusion that PPI should be 
given as an infusion after an initial bolus to patients with high risk bleeding ulcer. 
No studies compared bolus injections to infusions or had three experimental arms 
with an accepted placebo group. Therefore, this conclusion is not fully supported by 
a good randomized controlled trial, however, there is strong evidence based on this 
meta-analysis to support infusion therapy over bolus. 
There was statistical heterogeneity between studies which included rebleeding as 
an endpoint. Excluding the two of the three outlying studies resolved the 
heterogeneity36•43• Visually inspecting the studies in Figure 1 demonstrated that the 
Brunner study had an upper limit 95% confidence interval for it's Odds Ratio which 
failed to overlap with the lower limit of the 95% confidence interval of several other 
studies Odds Ratios36•37•39•41 •42•46-9• However, the lower limit of the 95% confidence 
interval for the Odds Ratios for both the Prassler49 and Daneshmend43 study failed to 
overlap with the upper limit of the 95% confidence interval of the Khuroo38 study 
Odds Ratio resulting in it being considered an outlier. Interestingly though, the 
lower limit of the 95% confidence intervals for both the Daneshmend and Prassler 
studies did overlap with the pooled Odds Ratio and it's 95% confidence interval. 
Two of the three studies which were most likely responsible for this statistical 
heterogeneity were in fact different methodologically from the others with respect to 
patient recruitment. All other studies had recruited patients from the Emergency 
rooms at the time of admission and included only those with high risk bleeding 
ulcers according to the Forrest classification. However, Daneshmend et. al.43 
included all sources of UGIB, with a peptic ulcer disease subgroup. Subjects were 
given medication prior to endoscopy and thus there was no stratification of patients 
thereby including many patients who were at low risk of recurrent bleeding. This 
approach would technically dilute the drug effect as many patients enrolled in their 
study would only have had a 5% chance of rebleeding55 • 
Brunner et. al. included only patients who developed PUD bleeding while in an 
intensive care unit for other severe illnesses36• This study demonstrated a very 
significant therapeutic gain with a narrow confidence interval in favor of PPI, despite 
its small size. This study was not blinded, though not the only one, and therefore 
investigator bias could have been a factor. However, there may be potential for more 
therapeutic gain in seriously ill patients. The Baylor Bleeding Score51 •52 is a 
predictive model for the probability of rebleeding in bleeding peptic ulcer disease 
after therapeutic endoscopy. It utilizes a combination of clinical and endoscopic 
criteria to predict the probability of rebleeding after effective endoscopic hemostasis. 
It would have predicted a high rate of recurrent bleeding in the Brunner study even 
with therapeutic endoscopy (none was employed during this study). It is thus 
possible that PPis are more efficacious in seriously ill patients36• This study was not 
blinded and again this has the potential to introduce investigator bias. 
PPI' s provided no therapeutic gain over placebo/H2RA with regard to mortality. 
The overall pooled Odds Ratio was nearly 1 indicating no difference between 
treatment and control. Surprisingly, the pooled odds ratio's were different when 
groups were compared based on whether or not therapeutic endoscopy had been 
performed. Studies were divided based on whether or not therapeutic endoscopy had 
been performed and the medication was given after endoscopy in both subgroups. 
The paper by Hasselgen et. al. was the only study to show a significant difference in 
mortality, however, it was in favor of the control group as 11 subjects died in the 
experimental group compared to only 1 in the placebo group42• We have no 
explanation for this finding. Most deaths in this study were due to co-morbid 
illnesses and unrelated to the UGIB in a period up to 3 months after presentation. 
It is not surprising that there was no difference in overall mortality in this meta-
analysis. There was an overall mortality rate of 3.8% in the control group. 
Calculating the size of a study needed to detect a 20% reduction in mortality would 
require nearly 100 000 individuals to be enrolled and it would require a sample size 
of 22000 patients to detect a 50% reduction in mortality. It is extremely unlikely that 
any further large studies looking for such a PPis benefit in the reduction of mortality 
will ever be performed. PPis are currently widely used in clinical practice and given 
the costs and time associated with performing randomized clinical trials, it would not 
make economic sense. 
Therapeutic endoscopy must continue to be the gold standard in the treatment of 
bleeding PUD. The meta-analysis by Cook and coworkers found a remarkable 
reduction in the rates of rebleeding and mortality regardless of the therapeutic 
method used (laser, heater probe or injection)56• The odds ratios were 0.57and 0.40 
respectively. Benefits of therapeutic endoscopy were even more significant when 
ulcers with stigmata with a higher risk of rebleeding were analyzed: these odds ratios 
were 0.23 for rebleeding and 0.62 for mortality respectively. There is a further 
reduction in rebleeding when PPis are given after therapeutic endoscopy in this 
meta-analysis, pOR of0.53 while there is a trend toward a decrease in mortality, 
pOR of0.65 when PPis are given post therapeutic endoscopy. Though there have 
been no head to head comparisons, the Odds Ratio for rebleeding without therapeutic 
endoscopy was still 0.54, approaching the odds ratio of the overall odds ratio for 
therapeutic endoscopy (Cook meta-analysis). However, given the significant 
reduction in mortality seen with therapeutic endoscopy, it must remain the primary 
treatment for bleeding from peptic ulcers. PPis should be considered for primary 
treatment of bleeding PUD where the expertise for therapeutic endoscopy do not 
exist. 
Somatostatin and octreotide have also been used in the past for actively 
bleeding PUD. A meta-analysis by Imperiale and Birgisson displayed similar 
reductions in the rates ofrebleeding as the PPI's67• The pooled odds ratio in that 
meta-analysis for overall rebleeding was 0.53 (0.43- 0.63). This raises the 
possibility of another therapeutic choice in the treatment of high risk PUD. There 
are no clinical trials comparing these two groups of medications and therefore direct 
comparisons are unavailable. There is no evidence available to suggest an added 
benefit of somatostatin or octreotide after therapeutic endoscopy or in conjunction 
with PPI's. 
In conclusion, we recommend the use of PPI in high risk bleeding peptic 
ulcers following appropriate therapeutic endoscopy. The appropriate dose and 
choice of agent is yet to be resolved, however, it would appear that infusions of 
intravenous PPis following an initial bolus provided more benefit than bolus PPis 
alone. This conclusion is supported by the fact that infusions ofPPis provide greater 
in vivo acid suppression than bolus PPis65• 
There have been no documented cost analysis for the use of PPI therapy in 
bleeding PUD. The cost involved with administration of PPI for a typical three day 
period (drug cost in Canada is approximately $60 per day) is less than the cost of 
repeated thereapeutic endoscopy, surgery and the risks involved with blood transfusion 
should the patient need blood. A thorough cost benefit analysis with multiple decision 
trees would be quite useful. 
5.2 The Debate between Heterogeneity and Publication Bias 
The assessment of heterogeneity is performed by calculating the Chi-Square 
statistic and by comparing overlapping confidence intervals visually whereas 
publication bias is assessed by plotting an effect size against the precision (sample 
size). The net result is that the two plots can take on very similar appearances 
particularly when the standard meta-analysis plot is arranged by sample size. 
Therefore, it seems that heterogeneity and publication bias are assessing a similar 
element within meta-analysis, variance. 
An extensive search of the literature was unable to discover an authoritative 
statistical review of heterogeneity and publication bias together. Figure 18 which 
plotted the width of the 95% confidence interval against sample size for rebleeding 
data demonstrated the existence of publication bias. This non-mathematically 
manipulated graphical presentation demonstrated that the confidence interval for 
many of the smaller studies is much narrower than that of some of the larger studies. 
These data could not be transposed over the standard meta-analysis to graphically 
compare the two. 
Finally, in the introduction, it was stated that heterogeneous data should not be 
combined with meta-analysis. However, if the heterogeneity can be explained, then 
it is reasonable to combine similar studies. An argument can be made against not 
combining heterogeneous data on the whole premise that the purpose of the 
systematic review is to provide an unbiased presentation of all available published 
data. Provided a thorough search had been performed, data should be attained from 
a multitude of sources which are distinct. That is so of this study which included 
data on patients from China, India, Arabic countries, Germany, Spain, the UK and 
the Netherlands. Data attained from such distinct groups and combined in a meta-
analysis provides the best overall summary available on the use of proton pump 
inhibitors in the bleeding peptic ulcer. 
This thesis summarized a large amount of data but there is still data which should 
be attained in further research. Two studies used oral PPI, one demonstrated a 
benefit in favour of the PPI38 and one showed no difference47• The smaller study 
was obviously not powered to detect a significant difference between treatment and 
control and a post hoc combination of the two studies does show a benefit in favour 
of oral PPI47• Neither of these studies used therapeutic endoscopy and are therefore 
more limited in their generalizability to the standard of care of upper GI bleeding in 
Canada. The future direction of research for PPI therapy in UGI bleeding could 
consist of comparing oral to intravenous PPI. Currently, drug costs for three days of 
treatment with intravenous PPI costs approximately $210.00 (-13.50/40 mg vial of 
pantoprazole) while an equivalent dose of oral PPI would cost approximately $40.00 
($2.20/40 mg tablet- community phamaceutical price. This comparison suggests 
that an equivalent oral dose of PPI be given as the intravenous dose (approximately 
172 mg/24 hours). The steps involved in this comparison would likely involve 
comparing intragastric pH in normal subjects given oral and intravenous PPI, then 
progressing to similar comparison with patients followed finally by a large 
equivalence study. 
H2RA's were considered to be equivalent to placebo for this meta-analysis as no 
large RCT or meta-analysis had been able to show a statistically significant benefit 
over placebo63•64• When this meta-analysis is compared to the data available on 
H2RA's, one very significant difference is obvious. The normal oral dose of a PPI 
for example is 20-40 mg per day, yet, the intravenous protocols with omeprazole 
utilized up to 172 mg per 24 hours. The normal oral ranitidine dose is 300 mg per 24 
hours and most bleeding trials included in the meta-analysis used 150 mg per 24 
hours while the large famotidine study used the standard oral dose ( 40 mg/24 hours) 
given intravenously. Therefore, it would appear that the H2RA studies were 
significantly flawed compared to the PPI studies. It is impossible to predict what the 
outcome of the H2RA studies would have been if they had administered a dose 
equivalent to eight times the normal oral dose rather than half or equivalent iv to oral 
dose. In addition, the H2RA's were almost exclusively delivered in a bolus fashion. 
Given that the PPI infusion showed a significant reduction in rebleeding and bolus 
PPI did not, perhaps the same would be true of the H2RA' s. Given the current 
standing of PPI in the treatment of the bleeding peptic ulcer, we are unlikely to see 
any further H2RA research. 
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Data structure 
Consider a meta-analysis ofk studies. When the studies have a binary outcome the results of each study can be 
presented in a 2x2 table (Table 1) giving the numbers of subjects who do or do not experience the event in each 
of the two groups (here called intervention and control). 
Table 1 Binary data 
Study i Event No event Total 
Intervention a; h; nu 
Control c, di n2i 
If the outcome is a continuous measure, the number of subjects in each of the two groups, their mean response and the 
standard deviation of their responses are required to perform meta-analysis (Table 2). 
Table 2 Continuous data 
Study i Group size Mean response Standard deviation 
Intervention nu lnts sd11 
Control n21 m21 sd2s 
Formulae 
Individual Study Responses: Binary outcomes 
For study i denote the cell counts as in Table I, and let llts = a1 + b1 , n21 = c1 + d1 , and N; = ~tt1 + ~~ . For 
the Peto method the individusl odds ratios are given by 
OR; =exp{(a1 -E[a1])/v1 } 
with its logarithm haviug standard error 
where E[ a1 ] = nli ( a1 + c1) I N1 (the expected number of events in the intervention group) and 
For other methods of combining trials, the odds ratio for each study is given by 
A 
OR1 = a1d1 I b1c1 
the standard error of the log odds ratio being 
se{ln( OR;)};;;;: ~11 a1 + 11 b1 + 11 c1 + 11 d1 
The risk ratio for each study is given by 
RR1 = (aJn 11 )1(cJn2J 
the standard error of the log risk ratio being 
se{ln(RR1)} = ~11 a1 + 11 c1 -llnli -11 n21 
The risk difference for each study is given by 
Where zero cells cause problems with computation of effects or standard errors, 0.5 is added to all cells ( a1, b1 , c1 , d1) 
for that study, except when a1 = c1 = 0 or b1 = d1 = 0 , when the relative effect measures OR; and RR1 are 
undefined. 
Individual Study Responses: Continuous outcomes 
Denote the number of subjects, mean and standard deviation as in Table 2, and let 
N, = "tt + n,., 
and 
s1 =~((n11 -l)sd~ +(n21 -1)sd~1)1(N1 -2) 
be the pooled standard deviation of the two groups. The weighted mean difference is given by 
A • A I 2 2 WMD = m11 - m21 wtth standard error se(WMD) = v sd11 I nli + sd21 I n21 
There are several popular formulations of the standardised mean difference. The one implemented in Meta View is 
Hedges adjusted g, which is very similar to Cohen's d, but includes an adjustment for small sample bias 
g1 = ((m 11 -m21 )1 s1)(1-31(4N, -9)) with standard error se(g1) = ~NJ(n11n21 )+ g: 1(2(N1 -3.94)). 
2 
Pooling Methods 
Mantel-Haenszel Methods for Combining Trials 
For each study, the effect size from each trial S1 is given weight w1 in the analysis. The overall estimate ofthe 
pooled effect, 8 MH is given by 
For combining odds ratios, each study's OR is given weight 
W; =b;C; IN;. 
~ 
and the logarithm of ORMH has standard error given by 
where 
R= l:a1d11N1 ; S= Lh1c1 1N1 ; 
PR = :L,(a1 +d1)aA IN;; PS = :L,(a1 +d1)b1c1 I N 12 ; 
QR = :L,(b1 +c)a1d1 I N 12 ; QS::::: :L,(b1 +c1)b1c1 IN; 
For combining risk ratios, each study's RR is given weight 
w1 ::::: [c1(a1 +b1)]1 Nl' 
~ 
and the logarithm of RRMH has standard error given by 
se{ln(RRMH)}::::: .J P I(R x S) 
where 
P::::: :L,(n11n21 (a1 +c1) -a1c1NJI N 12 ; R::::: :L,a,~1 IN,; S = :L,c,n11 I N 1 
For risk differences, each study's RD has the weight 
w1 ::::: "t1n21 I N1 
and iuJ MH has standard error given by 
where 
P::: L(a1b1n~1 +c1d1n~1 )1("t1n21N12 ); Q= L"t1n2;1 N 1 
The heterogeneity statistic is given by 
~ f A A 2 Q= k.twt(e, -eM") 
3 
where e is the log odds ratio, log relative risk or risk difference and the w; are the weights calculated as 
1 I se(@1 ) 2 • Under the null hypothesis that there are no differences in treatment effect between trials this follows a 
chi-squared distribution on k -1 degrees of freedom (where k is the number of studies contributing to the meta-
analysis). 
Inverse Variance Methods for Combining Trials 
Inverse variance methods are used to pool both standardised mean differences, and weighted mean differences for 
~ 
continuous data. In the general formula the effect size is defined to be 8 1 which is the trials SMD or WMD. The 
individual effect sizes are weighted according to the reciprocal of their variance (calculated as the square of the 
standard error given in the individual study section above) giving 
w1 =1/se(S1) 2 
These are combined to give a pooled estimate 
A :Lw,e, 
elv = "' 
.£.J w, 
with 
se{e/V} = 11 ~L W; 
The heterogeneity statistic is given by a similar formula as for the Mantel-Haesznel method, using the inverse variance 
form of the weights, w1 
Peto's Assumption Free Method for Combining Trials 
Here, the overall odds ratio is given by 
ORp""' =exp{Lw1 ln(O~)/Lw1 }, 
~ 
where the odds ratio OR1 is calculated using the approximate method described in the individual trial section, and the 
weights, w1 are equal to the bypergeometric variances, v1 • 
The logarithm of the odds ratio bas standard error 
se{In(ORp.,.)} = 11 ~L v, 
The heterogeneity statistic is given by 
Q= ~:V,{(tn0~)2 -(1n0Rp.,.,)2 }. 
DerSimonian and Laird Random Effects Models 
Under the nindom effects model, the assumption of a common treatment effect is relaxed, and the effect sizes are 
assumed to have a distribution 
4 
The estimate of 'r 2 is given by 
e = max{[Q -(k-1)]/[~:: W; -CI(w;2))/I W;],O}, where the W; are the inverse variance weights 
A 2 (calculated as 1 I se( 8;) ) for log OR, log RR. RD, WMD and SMD, as appropriate. 
The estimate of the combined effect for the heterogeneity may be taken as either the Mantel-Haenszel or the inverse 
variance estimate. Again, for odds ratios and risk ratios, the effect size is taken as the natural logarithm of the OR and 
RR. Each study's effect size is given weight 
w; = 1/(se(S;)2 +f 2 ) 
The pooled effect size is given by 
evL = (L W:SJI(L W:) 
and 
se{ e DL} = 11 ~I w; 
Note that in the case where the heterogeneity statistic Q is less than or equal to its degrees of freedom ( k -1) , the 
estimate of the between trial variation, f 2 , is zero, and the weights reduce to the those as given by the inverse variance 
method. 
Confidence intervals 
The 100(1-a)% confidence interval for e is given by 
9-se(S)<I>(l-a /2), to S+se(e)<I>(l-a/ 2) 
A 
where e is the log odds ratio, log relative risk, risk difference,mean difference or standardised mean difference, and 
<I> is the standard normal deviate. 
Test statistics 
In all cases, the test statistic is given by 
z=Sise(S) 
where the odds ratio or risk ratio is again considered on the log scale. 
5 
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